{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:45:41Z","timestamp":1765057541934},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,8]],"date-time":"2014-03-08T00:00:00Z","timestamp":1394236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12185-014-1541-y","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T02:21:42Z","timestamp":1394158902000},"page":"429-436","source":"Crossref","is-referenced-by-count":17,"title":["Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab"],"prefix":"10.1007","volume":"99","author":[{"given":"Kousaku","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaya","family":"Nakadate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Hashii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shirahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masue","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,8]]},"reference":[{"key":"1541_CR1","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","volume":"117","author":"C Neunert","year":"2011","unstructured":"Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190\u2013207.","journal-title":"Blood"},{"key":"1541_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12185-013-1370-4","volume":"98","author":"H Kashiwagi","year":"2013","unstructured":"Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98:24\u201333.","journal-title":"Int J Hematol"},{"key":"1541_CR3","unstructured":"Giulino LB, Bussel JB, Neufeld EJ; Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr. 2007;150:338\u201344, 344.e1."},{"key":"1541_CR4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","volume":"146","author":"DM Arnold","year":"2007","unstructured":"Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25\u201333.","journal-title":"Ann Intern Med"},{"key":"1541_CR5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2004.09.004","volume":"146","author":"J Wang","year":"2005","unstructured":"Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217\u201321.","journal-title":"J Pediatr"},{"key":"1541_CR6","first-page":"281","volume":"90","author":"T Taube","year":"2005","unstructured":"Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90:281\u20133.","journal-title":"Haematologica"},{"key":"1541_CR7","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","volume":"107","author":"CM Bennett","year":"2006","unstructured":"Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639\u201342.","journal-title":"Blood"},{"key":"1541_CR8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","volume":"50","author":"A Rao","year":"2008","unstructured":"Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50:822\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"1541_CR9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/pbc.21757","volume":"52","author":"BU Mueller","year":"2009","unstructured":"Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Pediatric Rituximab\/ITP Study Group, Glaser Pediatric Research Network, et al. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer. 2009;52:259\u201362.","journal-title":"Pediatr Blood Cancer"},{"key":"1541_CR10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12185-009-0387-1","volume":"90","author":"Y Torii","year":"2009","unstructured":"Torii Y, Yagasaki H, Tanaka H, Mizuno S, Nishio N, Muramatsu H, et al. Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome. Int J Hematol. 2009;90:174\u20136.","journal-title":"Int J Hematol"},{"key":"1541_CR11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/pbc.22036","volume":"53","author":"K Iesato","year":"2009","unstructured":"Iesato K, Hatakeyama N, Yamamoto M, Hori T, Inazawa N, Tsutsumi H, et al. Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab. Pediatr Blood Cancer. 2009;53:203\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"1541_CR12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s12098-009-0230-y","volume":"76","author":"M Dogan","year":"2009","unstructured":"Dogan M, Oner AF, Acikgoz M, Uner A. Treatment of chronic immune thrombocytopenic purpura with rituximab in children. Indian J Pediatr. 2009;76:1141\u20134.","journal-title":"Indian J Pediatr"},{"key":"1541_CR13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/tropej\/fmq033","volume":"57","author":"EC Citak","year":"2011","unstructured":"Citak EC, Citak FE. Treatment results of children with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. J Trop Pediatr. 2011;57:71\u20132.","journal-title":"J Trop Pediatr"},{"key":"1541_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2008.07487.x","volume":"144","author":"E Parodi","year":"2009","unstructured":"Parodi E, Rivetti E, Amendola G, Bisogno G, Calabrese R, Farruggia P, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol. 2009;144:552\u20138.","journal-title":"Br J Haematol"},{"key":"1541_CR15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12185-009-0269-6","volume":"89","author":"S Goto","year":"2009","unstructured":"Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O, et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;89:305\u20139.","journal-title":"Int J Hematol"},{"key":"1541_CR16","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","volume":"119","author":"VL Patel","year":"2012","unstructured":"Patel VL, Mah\u00e9vas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, et al. Outcome 5\u00a0years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989\u201395.","journal-title":"Blood"},{"key":"1541_CR17","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Amold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386\u201393.","journal-title":"Blood"},{"key":"1541_CR18","unstructured":"National Institute of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events, Version 3.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf ."},{"key":"1541_CR19","doi-asserted-by":"crossref","first-page":"e36698","DOI":"10.1371\/journal.pone.0036698","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One. 2012;7:e36698.","journal-title":"PLoS One"},{"key":"1541_CR20","doi-asserted-by":"crossref","unstructured":"Pe\u00f1alver FJ, Jim\u00e9nez-Yuste V, Almagro M, Alvarez-Larr\u00e1n A, Rodr\u00edguez L, Casado M, et al. On behalf of the multi-institutional retrospective Spanish Study Group on the use of rituximab in refractory ITP. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85:400\u20136.","DOI":"10.1007\/s00277-006-0123-3"},{"key":"1541_CR21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-008-0574-9","volume":"88","author":"K Alasfoor","year":"2009","unstructured":"Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol. 2009;88:239\u201343.","journal-title":"Ann Hematol"},{"key":"1541_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/adc.88.4.337","volume":"88","author":"PC Ng","year":"2003","unstructured":"Ng PC, Lee KK, Lo AF, Li CK, Fok TF. Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Arch Dis Child. 2003;88:337\u20139.","journal-title":"Arch Dis Child"},{"key":"1541_CR23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605\u201311.","journal-title":"J Clin Oncol"},{"key":"1541_CR24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/pbc.23130","volume":"58","author":"RF Grace","year":"2012","unstructured":"Grace RF, Bennett CM, Ritchey AK, Jeng M, Thornburg CD, Lambert MP, et al. Response to steroids predicts responses to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer. 2012;58:221\u20135.","journal-title":"Pediatr Blood Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1541-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1541-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1541-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:11:17Z","timestamp":1559437877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1541-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1541-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,8]]}}}